Essential thrombocythemia
Conditions
Brief summary
Durable Clinicohematologic Response (DCHR) Rate.
Detailed description
Change From Baseline in Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) Individual Fatigue Symptom Item Score., Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score., Change From Baseline in MFSAF v4.0 Total Symptom Score., Duration of Clinicohematologic Response (DOCHR)., Duration of Hematologic Remission (DOHR)., Number of Participants Who Experience Thrombotic Events., Number of Participants Who Experience Major Hemorrhagic Events., Disease Progression Rate., Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE.
Interventions
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Durable Clinicohematologic Response (DCHR) Rate. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline in Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) Individual Fatigue Symptom Item Score., Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score., Change From Baseline in MFSAF v4.0 Total Symptom Score., Duration of Clinicohematologic Response (DOCHR)., Duration of Hematologic Remission (DOHR)., Number of Participants Who Experience Thrombotic Events., Number of Participants Who Experience Major Hemorrhagic Events., Disease Progression Rate., Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE. | — |
Countries
Austria, Denmark, France, Germany, Hungary, Italy, Poland, Spain, Sweden
Outcome results
None listed